WuXi XDC today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in development and manufacturing of antibody-drug conjugates (ADCs).
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first cancer patients have started treatment with its investigational antibody-drug conjugate (ADC) SYD1875.